Oruka Therapeutics (ORKA) EBIT Growth (3y) (2013 - 2024)
Powered by 
Analysis
Oruka Therapeutics (ORKA) EBIT Growth (3y) (2013 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Oruka Therapeutics | 5.85 Bn | 4.12 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 13.58% |
| Mar 31, 2024 | 15.42% |
| Dec 31, 2023 | 32.31% |
| Sep 30, 2023 | 0.90% |
| Jun 30, 2023 | -14.63% |
| Mar 31, 2023 | -10.26% |
| Dec 31, 2022 | -6.60% |
| Sep 30, 2022 | -26.96% |
| Jun 30, 2022 | -28.76% |
| Mar 31, 2022 | -22.54% |
| Dec 31, 2021 | -54.94% |
| Sep 30, 2021 | -41.57% |
| Jun 30, 2021 | -30.91% |
| Mar 31, 2021 | -13.94% |
| Dec 31, 2020 | -6.06% |
| Sep 30, 2020 | 23.67% |
| Jun 30, 2020 | 38.23% |
| Mar 31, 2020 | 32.62% |
| Dec 31, 2019 | 33.22% |
| Sep 30, 2019 | 35.80% |